Magnolol
5 · 5′-diallyl-2 · 2′-dihydroxybiphenyl · Magnolia bark lignan · Relora (blend)
Last updated
At a glance
Overview
Why Magnolol Earned Its Spot in the Stack#
Magnolol is the workhorse lignan from Magnolia officinalis bark, and it has quietly become one of the most useful OTC tools for users managing the unglamorous side of physique work — cortisol on harsh cycles, sleep on tren, and the stress-eating that wrecks a deficit. Mechanistically it's a positive allosteric modulator at GABA-A receptors with notable activity at extrasynaptic δ-containing subtypes, which translates to a clean, non-hypnotic anxiolytic profile that doesn't blunt training drive the way phenibut or kava can.
The reputation comes from real human data, not just rodent work. A standardized Magnolia/Phellodendron blend (Relora-style, 750mg/day) produced a measurable ~18% reduction in salivary cortisol over four weeks in moderately stressed adults, alongside improved mood scores. That's the headline use-case in the bodybuilding and looksmaxxing community: an OTC adjunct that takes the edge off cortisol-driven catabolism during a cut, makes harsh orals more tolerable to sleep through, and complements (not replaces) tools like ashwagandha and phosphatidylserine.
"After 4 weeks of supplementation, salivary cortisol exposure was reduced by 18% in the Relora group compared to controls, with significant improvements in multiple mood state indices." — Talbott et al., J Int Soc Sports Nutr (2013)
What follows covers magnolol dosage ranges for both Relora-grade blends and concentrated ≥90% lignan products, the benefits worth expecting (and the ones that are overhyped), realistic side effects and the GABAergic stacking interactions that matter, the canonical stacks for on-cycle cortisol management and sleep, and how magnolol compares against the obvious alternatives — ashwagandha, phosphatidylserine, and honokiol.
How Magnolol works
Magnolol is the principal neolignan in Magnolia officinalis bark and the workhorse behind every "Relora-style" cortisol and sleep blend on the market. Its mechanism is unusually clean for a plant-derived compound: a flumazenil-reversible positive allosteric modulator of GABA-A receptors, layered on top of mild PPARγ and anti-inflammatory activity. That combination is what makes it interesting to physique-focused users running harsh orals, aggressive cuts, or anything else that drives the HPA axis into overdrive.
GABA-A Positive Allosteric Modulation#
Magnolol potentiates both phasic (synaptic) and tonic (extrasynaptic) GABAergic currents, with broad activity across α/β/γ subunit combinations and particularly strong efficacy at δ-containing extrasynaptic receptors — the population most responsible for tonic inhibition and baseline anxiolysis.
"Magnolol and honokiol enhanced the amplitude and slowed the decay of synaptic and extrasynaptic currents at both recombinant and native GABA(A) receptors, with pronounced efficacy at δ subunit-containing receptors." — Alexeev M. et al., Neuropharmacology, 2012
Practically, this is why magnolol feels different from a "GABA powder" supplement (which doesn't cross the BBB) or from valerian (which works through a less defined mechanism). The δ-receptor bias means it produces a steady tonic dampening of CNS arousal rather than a sharp sedative hit — useful for cortisol and rumination, not for knocking someone out.
Benzodiazepine-Site Binding and Sleep Architecture#
Magnolol's sleep-promoting effects share a binding site with classical benzodiazepines, but with markedly weaker affinity and no documented dependence liability at supplement doses.
"Magnolol-induced increases in NREM and REM sleep were completely antagonized by co-administration of flumazenil, demonstrating the involvement of the benzodiazepine site of the GABA(A) receptor." — Qiu LL. et al., Neuropharmacology, 2012
This is the mechanistic rationale for evening dosing in users dealing with tren insomnia, anadrol night sweats, or clen-driven sympathetic overdrive. It also explains the single most important interaction warning on the compound: stacking magnolol with benzodiazepines, Z-drugs, phenibut, kava, or alcohol produces additive depression at a shared binding site. Respect that and the rest of the profile is forgiving.
HPA-Axis Dampening and Cortisol Reduction#
The downstream consequence of tonic GABAergic potentiation is reduced hypothalamic drive on the HPA axis. In moderately stressed adults, a standardized Magnolia/Phellodendron blend produced a measurable cortisol drop over four weeks:
"After 4 weeks of supplementation, salivary cortisol exposure was reduced by 18% in the Relora group compared to controls, with significant improvements in multiple mood state indices." — Talbott SM. et al., Journal of the International Society of Sports Nutrition, 2013
For physique-focused users, this is the headline mechanism. Cortisol drives catabolism of lean tissue, central fat deposition, evening carb cravings, and sleep fragmentation — all of which compound on harsh cycles and aggressive deficits. Magnolol doesn't suppress the adrenals directly; it lowers the upstream drive. That's the right pharmacology for an adjunct: it tames overshoot without crippling the system.
PPARγ Activation and Adipocyte Browning#
Beyond the CNS, magnolol has documented activity at PPARγ, the master regulator of adipocyte differentiation and mitochondrial biogenesis in fat tissue.
"Magnolol activates PPARγ and upregulates UCP1 protein levels, promoting browning of white adipose tissue and enhancing lipid metabolism." — Wang Y. et al., Med Research, 2025
This is a real but modest effect — magnolol is not a fat-loss compound and shouldn't be framed as one. The clinical relevance is that the metabolic tail of the molecule is at least neutral-to-favorable for users running it during a cut, rather than working against them the way some sedatives (mirtazapine, certain antihistamines) do by promoting weight gain.
Pharmacokinetic Reality: Why Dosing Is Front-Loaded and Multi-Daily#
Magnolol is extremely lipophilic and undergoes aggressive Phase II conjugation on first pass. Free oral bioavailability in rats sits in the low single digits; lecithin-based micelle formulations can push it an order of magnitude higher.
"Magnolol oral bioavailability in rats was increased from 2.01% (free drug) to 20.02% by formulating with self-assembling lecithin-based micelles." — Lin HL. et al., International Journal of Nanomedicine, 2021
Combined with a parent half-life of roughly 1–2 hours, this is why the Kalman and Talbott trials used 250 mg three times daily rather than a single bolus, and why sleep-focused protocols front-load 30–60 minutes pre-bed. Taking it with a fat-containing meal meaningfully improves absorption — the compound is essentially insoluble in water, and a dry capsule on an empty stomach leaves a lot of lignan on the table. Phospholipid-formulated products (lecithin complexes, liposomal extracts) are worth the premium if the budget allows; standard bark extract works fine if dosed with food.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 100–200 mg | 3× daily | Documented entry-level range |
| Mid | 200–400 mg | 3× daily | Most commonly studied range |
| High | 400–800 mg | 3× daily | Standardized Magnolia/Phellodendron blends (Relora-style) are dosed 250mg three times daily in the published trials. For sleep-focused use, dosing is front-loaded 30–60 minutes pre-bed. Concentrated (≥90% lignan) products land at the lower end of the listed dose range — read the label, as 200mg of high-purity magnolol can exceed the lignan content of a full 750mg/day Relora protocol. |
Cycle length & outcomes
Documented cycle
4–8 weeks
Plateau after
8 wks
Cycle Notes#
Magnolol is a non-hormonal, non-suppressive GABAergic adjunct, so the "cycle" concept here is closer to a supplement run than an AAS protocol. No loading phase, no taper, no PCT, no HPG impact. The two variables that matter are dose and duration — and both are driven by the goal, not by bodyweight.
| Goal | Cycle Length | Daily Dose (standardized extract) | Timing |
|---|---|---|---|
| Cortisol management on cycle (orals, tren, hard cuts) | 4–8 weeks | 750 mg (250 mg × 3) Relora-blend, or 400–600 mg high-% bark extract split | AM / midday / PM |
| Sleep onset on harsh cycles (tren, anadrol, clen) | Run for duration of offending compound | 200–400 mg standardized extract | 30–60 min pre-bed |
| Off-cycle / bridge cortisol clean-up | 4–6 weeks alongside SERM PCT | 500–750 mg/day | Split AM / PM |
| Stress-eating during aggressive deficit | 4–8 weeks | 750 mg/day Relora-blend | Split with meals |
| Daily anxiolytic / chronic stress load | 4–6 weeks, then 5-on/2-off | 200–400 mg | Evening |
| Concentrated magnolol (≥90% purity) | 4–8 weeks | 100–400 mg | Split or evening |
The clinical anchor is Talbott 2013 and Kalman 2008, both of which ran 250 mg of Relora three times daily for 4–6 weeks and measured meaningful endpoints at that dose.
"After 4 weeks of supplementation, salivary cortisol exposure was reduced by 18% in the Relora group compared to controls, with significant improvements in multiple mood state indices." — Talbott et al., JISSN 2013
Onset Timing#
Acute effects (sleep onset, anxiolysis) are perceptible from the first dose — magnolol crosses the BBB readily and Tmax is roughly 1 hour. The Qiu 2012 EEG work showed shortened NREM latency after a single dose, and the effect was fully blocked by flumazenil, confirming the benzodiazepine-site mechanism.
"Magnolol-induced increases in NREM and REM sleep were completely antagonized by co-administration of flumazenil, demonstrating the involvement of the benzodiazepine site of the GABA(A) receptor." — Qiu et al., Neuropharmacology 2012
Cortisol / HPA-axis effects are slower. The 18% salivary cortisol reduction in Talbott 2013 was measured at the 4-week mark, not day 3. Plan on 2–4 weeks before the cortisol benefit shows up in mood, sleep depth, and the subjective "edge off" that on-cycle users are looking for. Running it for 7–10 days and calling it a dud is the most common mistake.
Loading and Tapering#
Neither is necessary.
- No loading phase. Magnolol's short half-life (~1–2 hours for parent compound) and lack of receptor downregulation at therapeutic doses mean steady-state exposure is established within a day. The 3×/day Relora cadence exists because of the short half-life, not because of any kinetic build-up.
- No taper required. Unlike benzodiazepines, magnolol shows no evidence of GABA-A receptor downregulation, dependence, or withdrawal in the published literature. Discontinuation is abrupt and uneventful.
- Cycling rationale. The 4–8 week cycle window isn't safety-driven — it's pragmatic. The published trials don't extend beyond ~6 weeks, and subjective tolerance to the anxiolytic effect appears modest but real over longer runs. A 5-on/2-off pattern preserves the acute anxiolytic punch for users running it indefinitely.
Dose Calibration — Read the Label#
This is where most users get it wrong. The two product categories deliver radically different active lignan loads at the same capsule weight:
| Product Type | Lignan Content | Equivalent Daily Dose |
|---|---|---|
| Relora® blend (Magnolia + Phellodendron, ~1.5–2% lignans) | ~15 mg lignan / 750 mg blend | 750 mg/day (clinical) |
| Standardized bark extract (≥2% honokiol+magnolol) | ~10–20 mg lignan / 500 mg | 400–800 mg/day |
| High-purity magnolol/honokiol (≥90%) | 180+ mg lignan / 200 mg | 100–400 mg/day |
A 200 mg capsule of 90% magnolol contains more active lignan than a full 750 mg daily Relora protocol. Users who switch from Relora to a concentrated product without adjusting the dose end up oversedated; users who run concentrated product at "Relora doses" (750 mg × 3) are stacking far above any published exposure.
Bloodwork Cadence#
No magnolol-specific monitoring is required at conventional doses. Standard on-cycle bloodwork (lipids, LFTs, CBC, hormones) covers it.
- Conventional doses (Relora-blend at 750 mg/day, or standardized extract at 400–800 mg/day): no additional labs.
- Concentrated magnolol/honokiol >800 mg/day for >8 weeks: add LFTs to the on-cycle panel. Honokiol's hepatic AMPK activity and magnolol's CYP3A4/2C9 interaction profile justify a periodic check, particularly when stacked with hepatotoxic orals.
- CYP3A4 substrates in the medication list (some statins, certain immunosuppressants): the herb-drug interaction signal is dose-dependent and most relevant at concentrated-product exposures. Standardized bark extract at clinical doses has not produced clinically meaningful interaction reports.
Stacking Cadence Within a Cycle#
Magnolol layers cleanly into existing protocols without timing conflicts:
- With ashwagandha (KSM-66 600 mg/day) + phosphatidylserine (300–600 mg pre-bed): the canonical cortisol stack. Run all three for the duration of the AAS cycle.
- With glycine (3 g) + apigenin (50 mg) pre-bed: sleep stack for tren / anadrol nights.
- With SERM-based PCT: run continuously through PCT to blunt cortisol-driven catabolism. Magnolol does not interfere with HPG recovery.
- Avoid stacking with phenibut, kava, alcohol, benzodiazepines, or Z-drugs — magnolol is a benzodiazepine-site GABA-A PAM and the additive sedation is real, not theoretical.
The bottom line: a 4–8 week run at 250 mg of Relora three times daily — or the equivalent in higher-purity extract — is the evidence-anchored protocol. Effects on sleep are immediate; effects on cortisol take a month. No loading, no tapering, no PCT impact, and no bloodwork beyond what the rest of the cycle already requires.
Risks & mistakes
Common (most users)#
- Mild sedation / drowsiness — the expected pharmacology, not a malfunction. Magnolol's GABA-A potentiation is dose-dependent; if daytime doses feel heavy, front-load the bulk of the daily total to the evening dose 30–60 minutes pre-bed and keep the AM/midday dose ≤200mg of standardized extract.
- Next-morning grogginess — most often seen at >400mg evening doses or when a high-purity (≥90% lignan) product is being run at Relora-blend volumes. Drop the evening dose 25–50% for three nights and reassess.
- GI upset, loose stool, mild nausea — typically driven by the Phellodendron fraction in Relora-style blends rather than magnolol itself. Administering with food (a small fat-containing meal also helps the lipophilic absorption) resolves most cases.
- Dry mouth, mild headache — uncommon at conventional doses, more frequent at the 600–800mg/day upper bound. Hydration plus dose reduction.
- Vivid dreams — anecdotally common during the first week as REM architecture shifts (consistent with the Qiu et al. EEG data showing increased REM):
"Magnolol-induced increases in NREM and REM sleep were completely antagonized by co-administration of flumazenil, demonstrating the involvement of the benzodiazepine site of the GABA(A) receptor." — Qiu et al., Neuropharmacology (2012)
Uncommon (dose-dependent or individual)#
- Pronounced sedation / "weighted" feeling — emerges above ~600mg/day of standardized extract, or at lower doses of high-purity (≥90%) magnolol products. The δ-subunit extrasynaptic activity reported by Alexeev et al. produces a tonic-inhibition flavor that some users perceive as flatness rather than calm. Back off to the 200–400mg/day band.
- Reduced training drive / blunted aggression — a predictable consequence of HPA-axis dampening. Useful on a cut, counterproductive in a strength block. Move dosing entirely to the evening or cycle 5-on / 2-off around heavy training days.
- Lightheadedness on standing — magnolol has mild vasorelaxant activity; relevant when stacked with telmisartan, cialis, or other on-cycle blood pressure tools. Check resting BP and split the dose.
- Loose stools persisting >1 week — usually the Phellodendron component in blends. Switching to a standalone magnolol/honokiol product (no berberine-class alkaloids) resolves it.
- Drug-interaction territory at high doses — magnolol modulates CYP3A4 and CYP2C9. When concentrated products are run >600mg/day for extended periods alongside CYP3A4-sensitive substrates (some statins, tacrolimus, certain orals), pull periodic LFTs and review the stack.
Rare but serious#
- Excessive CNS depression in combined GABAergic stacks — magnolol shares the benzodiazepine binding site. Layered onto alcohol, phenibut, kava, gabapentinoids, or prescription benzodiazepines, the additive depression can exceed what each agent would predict on its own. Warning signs: ataxia, slurred speech, profound sedation. Discontinue and let the stack wash out.
- Allergic / hypersensitivity reactions — rash, pruritus, facial swelling. Rare, but standardized bark extract is still a botanical with multiple constituents. Discontinue immediately on any urticarial or angioedematous reaction.
- Hepatic enzyme elevations — not flagged in the standardized-extract trials at 750mg/day for 4–6 weeks, but theoretically possible with concentrated magnolol/honokiol products at sustained high doses. If running ≥800mg/day for >8 weeks, ALT/AST should be on the routine bloodwork panel.
Hard contraindications#
- Pregnancy and lactation — uterotonic activity of magnolia constituents is documented in rodent literature. Do not run during either.
- Concurrent benzodiazepines, Z-drugs, barbiturates, or phenibut — magnolol occupies the benzodiazepine site of GABA-A. Stacking is additive and unpredictable.
- Alcohol intoxication / heavy drinking sessions — additive CNS depression. Treat magnolol like a benzodiazepine when alcohol is on the table.
- Concurrent opioids, sedating antihistamines, or other prescription CNS depressants — additive sedation; coordinate the broader stack rather than layering blindly.
- Pre-operative period — discontinue at least 1 week prior to any procedure involving general anaesthesia, given the GABA-A interaction.
Gender and PCT considerations#
Magnolol has no androgenic, estrogenic, or progestational activity in the published profile. There is no virilization risk for female users and no aromatization concern for males. Dosing is identical across sexes — bodyweight-independent and non-hormonal.
For PCT: magnolol does not suppress the HPG axis and does not require PCT. It complements PCT by managing the cortisol elevation that erodes recovering lean mass — it does not restore LH/FSH or replace a SERM. Running 500–750mg/day of standardized extract alongside clomid or enclomiphene through PCT and the bridge weeks afterwards is the standard pattern, and one of the cleanest use cases for the compound in a physique-focused stack.
FAQ — Magnolol
Research & citations
6 studies cited on this page.
Conclusion
Magnolol earns its spot as a targeted ancillary for stress management, sleep onset, and cortisol blunting in physique- and aesthetics-focused stacks. Effects on GABA-A signaling are pronounced enough to matter on cycle, but low enough noise for daily use outside of heavy sedative stacks.
Key takeaways:
- Standard dose: 250 mg three times daily of Relora-style blends; 200–400 mg/day (split AM/PM or pre-bed) for high-purity magnolol/honokiol extracts
- Oral route is preferred; low bioavailability makes formulation quality and purity relevant for effect
- Cycle length: 4–8 weeks during cycles/cuts or as a bridge post-cycle; no PCT required
- Stacks well with ashwagandha, phosphatidylserine, and glycine depending on target (cortisol, sleep, or overall stress)
- Headline benefits: ~18% drop in 4-week cortisol exposure, favorable subjective mood/sleep quality, GABAergic synergy without next-day fog at standard dosing (Talbott 2013)
- Key risk: avoid stacking with benzodiazepines, Z-drugs, or heavy CNS depressants due to additive GABAergic effects
Magnolol is not a mass builder or fat burner, but as an on-cycle stress, sleep, and cortisol modulator, it runs clean, stacks flexibly, and deserves a spot in advanced recovery protocols.